Carson City, Nevada--(Newsfile Corp. - August 19, 2019) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has received approval from the Board of Directors to commence a Family Practice (BC) - Observational Study of its ebalance device (the "Observational Trial", or the "Study").
In order to commence the documentation for this Observational Trial, the Company will begin recruitment of a primary investigator immediately. The Study is to be conducted in a family practice medical clinic under the guidance and supervision of a Qualified Investigator (QI) who is a family practice physician (MD, CCFP) licensed in the province of British Columbia, Canada.
The ebalance device has received the Certificate of Conformity as Class A (professional use) and Class B (in-home use) device from LabTest Certification Inc. ("LabTest"). To qualify the device, LabTest used CSA, CE and UL Standards for electrical safety and emissions. The primary objective of the Observational Study will be to further confirm safety with a secondary objective looking at baseline chronic care and complex care biometrics in a clinical family practice setting.
Data from this Family Practice (BC) - Observational Study will be shared with Health Canada and used to further support the Company's application to the US Food and Drug Administration's Premarket Notification 510(k) program to clear ebalance for sale in the USA.
About Cell MedX Corp. (OTCQB: CMXC)
Cell MedX Corp. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, Parkinson's disease, high blood pressure, neuropathy and kidney function. The final report on the Observational Clinical Trials has been received by Health Canada. For more information about the Company and its technology please visit our website at www.cellmedx.com/investors/overview/. For the Company's newsletter please visit www.cellmedx.com/media/newsletters/
On behalf of the Board of Directors of Cell MedX Corp.
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
Cell MedX Corp.
For further information visit: www.cellmedx.com.
Or phone: 1-844-238-2692
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47034